Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
23.36
+0.29 (1.28%)
At close: Aug 21, 2026, 4:00 PM EDT
23.03
-0.33 (-1.40%)
After-hours: Aug 21, 2026, 7:30 PM EDT
Vor Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 107.86 | 396.49 | 81.95 | 31.36 | 57.71 | 119.8 |
Short-Term Investments | 358.27 | 58.72 | 9.98 | 105.82 | 172.54 | 87.67 |
Cash & Short-Term Investments | 466.13 | 455.21 | 91.93 | 137.18 | 230.25 | 207.47 |
Cash Growth | 132.41% | 395.19% | -32.99% | -40.42% | 10.98% | 327.43% |
Prepaid Expenses | 5.88 | 1.15 | 4.2 | 3.15 | 4.37 | 4.84 |
Other Current Assets | 3.1 | 1.75 | 0.38 | 0.48 | 2.34 | 2.09 |
Total Current Assets | 475.11 | 458.11 | 96.51 | 140.8 | 236.95 | 214.4 |
Property, Plant & Equipment | 3.37 | 3.47 | 41.59 | 50.1 | 57.08 | 22.52 |
Other Long-Term Assets | 2.58 | 2.55 | 4.8 | 7.23 | 5.34 | 5.67 |
Total Assets | 481.05 | 464.13 | 142.89 | 198.13 | 299.37 | 242.59 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4 | 5.13 | 1.51 | 0.82 | 1.77 | 1.55 |
Accrued Expenses | 20.48 | 19.76 | 12.89 | 10.93 | 8.08 | 6.34 |
Current Portion of Leases | 0.34 | 0.28 | 4.22 | 3.83 | 3.27 | 1.84 |
Other Current Liabilities | - | - | - | - | - | 0.43 |
Total Current Liabilities | 24.81 | 25.17 | 18.61 | 15.57 | 13.12 | 10.15 |
Long-Term Leases | 2.54 | 2.72 | 27.62 | 31.83 | 35.64 | 16.17 |
Other Long-Term Liabilities | 653.89 | 600.55 | - | - | - | - |
Total Liabilities | 681.25 | 628.44 | 46.23 | 47.4 | 48.76 | 26.33 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0 |
Additional Paid-In Capital | 1,236 | 988.6 | 553.62 | 490.87 | 473.59 | 346.38 |
Retained Earnings | -1,435 | -1,153 | -456.99 | -340.08 | -222.22 | -130.12 |
Comprehensive Income & Other | -0.92 | 0.04 | 0.02 | -0.08 | -0.77 | - |
Total Common Equity | -200.2 | -164.31 | 96.66 | 150.72 | 250.61 | 216.26 |
Shareholders' Equity | -200.2 | -164.31 | 96.66 | 150.72 | 250.61 | 216.26 |
Total Liabilities & Equity | 481.05 | 464.13 | 142.89 | 198.13 | 299.37 | 242.59 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2.88 | 3 | 31.83 | 35.66 | 38.91 | 18.01 |
Net Cash (Debt) | 463.25 | 452.21 | 60.1 | 101.52 | 191.33 | 189.46 |
Net Cash Growth | 130.97% | 652.48% | -40.80% | -46.94% | 0.99% | 526.38% |
Net Cash Per Share | 14.90 | 45.81 | 17.49 | 30.22 | 96.75 | 113.33 |
Filing Date Shares Outstanding | 59.16 | 48.85 | 6.24 | 3.41 | 3.32 | 1.87 |
Total Common Shares Outstanding | 54.46 | 38.72 | 6.24 | 3.39 | 3.3 | 1.86 |
Working Capital | 450.29 | 432.93 | 77.9 | 125.23 | 223.83 | 204.25 |
Book Value Per Share | -3.68 | -4.24 | 15.49 | 44.40 | 75.95 | 116.35 |
Tangible Book Value | -200.2 | -164.31 | 96.66 | 150.72 | 250.61 | 216.26 |
Tangible Book Value Per Share | -3.68 | -4.24 | 15.49 | 44.40 | 75.95 | 116.35 |
Machinery | - | - | 17.15 | 17.4 | 15.64 | 8.77 |
Construction In Progress | - | - | 0.04 | 0.15 | 1.04 | - |